CMV in kidney transplants in the tacrolimus-mycophenolate era.
Cailhier
J F
JF
Service de néphrologie, Hôpital Maisonneuve-Rosemont and Université de Montréal, Montréal, Canada.
Boucher
A
A
Béliveau
C
C
Poirier
L
L
Delorme
J
J
Weiss
K
K
Laverdière
M
M
Hébert
M J
MJ
Pichette
V
V
Dandavino
R
R
D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D009173:Mycophenolic Acid / Q000009:adverse effects* / Q000031:analogs & derivatives; D012189:Retrospective Studies; D016559:Tacrolimus / Q000009:adverse effects*
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D015774:Ganciclovir; D016559:Tacrolimus